RSV INFECTION

This early-stage study tested two experimental RSV vaccines given as nose drops to 60 children. Some children already had RSV antibodies (ages 1-5), while others did not (ages 6 months-2 years). The main goal was to check safety and whether the vaccine triggered an immune respons…

This early-stage study tested a new vaccine designed to protect against two respiratory viruses: RSV and hMPV. It involved 385 healthy adults aged 60 to 75 who received a single shot of different vaccine doses. The main goals were to check the vaccine's safety and see how well it…

This study tested an experimental oral drug called EDP-323 in 142 healthy adults who were intentionally infected with RSV. The goal was to see if the drug is safe and can reduce the amount of virus in the body compared to a placebo. The trial has been completed, and results will …

This study tested a new medicine called clesrovimab in over 1,000 infants and children at high risk for severe RSV disease. The goal was to see if it is safe and works as well as the current standard treatment, palivizumab. Participants received either clesrovimab or palivizumab …

This study looked at how the immune system of older adults (ages 60-75) responds to the respiratory syncytial virus (RSV). Researchers exposed 28 healthy volunteers to a controlled dose of RSV to track their immune reactions and any side effects. The goal was to find better targe…